My Member
Message Center
trending topics
market reports
-
Visit MEDICAL JAPAN 2023 TOKYO and take full advantage of the business opportunities!
2023-09-01
-
US to distribute 400 million free N95 masks at CVS, Walgreens in COVID fight
2022-01-21
-
Ethiopia receives additional 2.2 mln doses of Chinese-donated COVID-19 vaccines
2022-01-21
-
Hong Kong researchers say they develop novel material able to kill COVID-19 virus
2022-01-14
-
10 million more Chinese doses on way for Kenya
2022-01-14
-
Sino-African ties on track for a brighter future
2022-01-07
-
Efforts urged to boost COVID-19 vaccine production capacity in poor countries
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
Zimbabwe buoyed by Chinese jabs
2021-12-31
2022 MEDICA Exhibitor’s Recommendation--Shanghai Kehua Bio-Engineering Co., Ltd.
2022-11-11
MEDICA is the leading international platform for the medical technology industry. For more than 50 years, it has been a must-attend event in the annual calendar of trade visitors from all areas of the healthcare industry.
Shanghai Kehua Bio-Engineering Co., Ltd. will participate in this event at Booth: 17 E41-6 and look forward to meeting you.
Company Profile
Shanghai Kehua Bio-Engineering Co., Ltd. (hereinafter referred to as KHB, Stock code: 002022.SZ) is founded in 1981. It was the 1st publically listed IVD Company in China. Over the last 41 years, KHB has a full-line diagnostic products of immune diagnosis, Clinical Chemistry diagnosis, molecular diagnosis and POCT, and developed into a high-tech company that integrates R&D, manufacturing and business.
Headquartered in Shanghai, KHB has set up R&D centers and production bases in Italy and China. Currently, the company has over 2,000 employees and 10,000 distributors. Being a hi-tech enterprise certified by Shanghai, KHB has established postdoctoral research station, Shanghai Research Center for Immune Diagnostic Engineering and Shanghai Innovation Center for Clinical IVD Reagents.
With its mission of "Caring for life, dedicate to excellence", vision of “To become a leading company on a global stage” and its values of “customer first, innovation, collaboration, responsibility, and pragmatism, driven by innovation and lean management, KHB focuses on in vitro diagnostics and is committed to welfare of human beings.
Leading Products Display
Shanghai Kehua Bio-Engineering Co., Ltd. will participate in this event at Booth: 17 E41-6 and look forward to meeting you.
Company Profile
Shanghai Kehua Bio-Engineering Co., Ltd. (hereinafter referred to as KHB, Stock code: 002022.SZ) is founded in 1981. It was the 1st publically listed IVD Company in China. Over the last 41 years, KHB has a full-line diagnostic products of immune diagnosis, Clinical Chemistry diagnosis, molecular diagnosis and POCT, and developed into a high-tech company that integrates R&D, manufacturing and business.
Headquartered in Shanghai, KHB has set up R&D centers and production bases in Italy and China. Currently, the company has over 2,000 employees and 10,000 distributors. Being a hi-tech enterprise certified by Shanghai, KHB has established postdoctoral research station, Shanghai Research Center for Immune Diagnostic Engineering and Shanghai Innovation Center for Clinical IVD Reagents.
With its mission of "Caring for life, dedicate to excellence", vision of “To become a leading company on a global stage” and its values of “customer first, innovation, collaboration, responsibility, and pragmatism, driven by innovation and lean management, KHB focuses on in vitro diagnostics and is committed to welfare of human beings.
Leading Products Display
- HIV
- ZY-400
- ZY-260
- Polaris c1000
Polaris series integrate high efficiency of testing, flexible modular combination, and intelligent management. With its high throughput, Polaris series are designed for large clinical laboratories, third-party laboratories and health screening Centre.
Polaris c1000 clinical chemistry analyzer has very remarkable characteristics, that are, 200 reagent positions which is the highest among similar products, and the only one who has customized stirring parameters to set stirring frequency. It can simultaneously analyze 98 testing projects and has the most wavelengths of 16.
Polaris c1000 clinical chemistry analyzer has very remarkable characteristics, that are, 200 reagent positions which is the highest among similar products, and the only one who has customized stirring parameters to set stirring frequency. It can simultaneously analyze 98 testing projects and has the most wavelengths of 16.
- Polaris c2000
label :
Medica
